The EGFR inhibitor erlotinib has been evaluated in two clinical trials, but was determined in both to not provide clinical benefit to breast cancer patients, even when incorporating knowledge of EGFR expression levels in the primary tumor [79, 80]. Here, EGFR is linked to breast carcinoma.